Delving into the Latest Updates on Technische Universität Braunschweig with Synapse

概览

疾病领域	数量

肿瘤	2
神经系统疾病	2
免疫系统疾病	2

排名前五的药物类型	数量

抗体融合蛋白	2

排名前五的靶点	数量

NMDA receptor(谷氨酸[NMDA]受体复合体)	2

关联

2

项与 Technische Universität Braunschweig 相关的药物

GluN1-GluN2B-Fc (Yumab)

靶点

NMDA receptor

作用机制

NMDA receptor拮抗剂

在研机构

Technische Universität Braunschweig [+1]

原研机构

Yumab Gmbh [+1]

在研适应症

抗-N-甲基-D-天冬氨酸受体脑炎

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

GluN1-GluN2A-Fc (YUMAB)

靶点

NMDA receptor

作用机制

NMDA receptor拮抗剂

在研机构

Technische Universität Braunschweig [+1]

原研机构

Yumab Gmbh [+1]

在研适应症

抗-N-甲基-D-天冬氨酸受体脑炎

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

1

项与 Technische Universität Braunschweig 相关的临床试验

DRKS00006069

/ CompletedN/A

Consequences of Child Neglect and Maltreatment under Different Intervention Conditions (TP TREAT-Part) - GROW&TREAT

开始日期2014-04-07

申办/合作机构

Technische Universität Braunschweig

100 项与 Technische Universität Braunschweig 相关的临床结果

登录后查看更多信息

0 项与 Technische Universität Braunschweig 相关的专利（医药）

登录后查看更多信息

29,362

项与 Technische Universität Braunschweig 相关的文献（医药）

2025-02-01·Biochemical Pharmacology

Runcaciguat activates soluble guanylyl cyclase via the histidine essential for heme binding and nitric oxide activation

Article

作者: Rühle, Anne ; Elgert, Christin ; Mathar, Ilka ; Wittrien, Theresa ; Sandner, Peter ; Behrends, Sönke

Soluble guanylyl cyclase (sGC) is a well-established pharmacological target for the treatment of acute angina pectoris, pulmonary hypertension and heart failure. Histidine 105 in the heme binding pocket of sGC is a crucial residue for heme binding and natural enzyme activation by NO. It was assumed that the heme-free sGC mutants α₁/β₁H105F and α₁/β₁H105A were valuable research tools for studying NO independent sGC activators. These mutants have been used in drug screening and animal models. We confirm that the first generation of sGC activators cinaciguat and BAY 60-2770 activate the α₁/β₁H105F and α₁/β₁H105A mutants. In contrast, we show that the second generation sGC activators runcaciguat and BAY 543 only activate heme-free sGC when the β₁H105 residue is present. By testing runcaciguat in β₁ H105F knock-in mice, we confirm this histidine-dependency in vivo. We propose a novel classification of sGC activators, distinguishing between the histidine-dependent activators runcaciguat and BAY 543 and the histidine-independent activators cinaciguat, BAY 60-2770 and BI703704. The histidine-dependency of some of the sGC activators provides a compelling rationale for a re-evaluation of previous research and drug development programs based on sGC histidine mutants. Whether the classification of sGC activators based on the activation mechanism also makes a therapeutic difference needs to be clarified in the future.

2025-01-13·Organometallics

Importance of Ligand Fine-Tuning: Alkyne Metathesis with Molybdenum Alkylidyne Complexes Supported by Phenyl-tert-butoxysilanolate Ligands

作者: Tamm, Matthias ; Ludwig, Tobias ; Bannenberg, Thomas ; Neitzel, Angelika ; Bockfeld, Dirk

The phenyl-tert-butoxysilanols Ph(tBuO)₂SiOH and Ph₂(tBuO)SiOH were prepared and used for the synthesis of the molybdenum 2,4,6-trimethylbenzylidyne complexes [MesCMo{OSi(OtBu)₂Ph}₃] (1) and [MesCMo{OSi(OtBu)Ph₂}₃] (2) from mer-[MesCMoBr₃(dme)] (dme = dimethoxyethane, Mes = 2,4,6-trimethylphenyl).The mol. structures of 1 and 2 were determined by X-ray diffraction anal., revealing a secondary molybdenum-oxygen interaction and a chelating κ²O,O′ coordination mode of one of the siloxide ligands in the case of 1.Treatment of 1 and 2 with an excess of 3-hexyne (EtCCEt) afforded the corresponding propylidyne (EtCMo) complexes, which are in equilibrium with labile metallacyclobutadiene complexes as evidenced by variable-temperature NMR spectroscopy.Single crystals of [(Et₃C₃)Mo{OSi(OtBu)Ph₂}₃] (2-MCBD) have been isolated at low temperature, providing a rare example of a crystallog. characterized molybdenacyclobutadiene.The alkylidyne complexes 1 (n = 1) and 2 (n = 2) complete the series of available alkyne metathesis (pre-)catalysts [RCMo{OSi(OtBu)_3-nPh_n}₃] (n = 0-3), and their catalytic performance in the metathesis of internal and terminal alkynes was investigated and compared, if available, with the previous members of this series (n = 0, 3).

2025-01-02·The Journal of Adhesion

Effect of laser pre-treatment on adhesive joint performance and evaluation of interfacial strain distribution using mechanoluminescence

作者: Fujio, Yuki ; Gundlach, Christian ; Steinberg, Julian ; Houjou, Keiji ; Horiuchi, Shin ; Yase, Kiyoshi ; Terasaki, Nao ; Akiyama, Haruhisa ; Hirakawa, Rio ; Shimamoto, Kazumasa ; Hartwig, Sven ; Sakata, Yoshitaro

In this study, factors that improve bonded joints structural response through laser surface pre-treatment on aluminum surfaces were investigated.Specifically, the focus was put on analyzing the laser treatment conditions, formation of the interface structure, and behavior of interface strength at the adhesive interface.The results revealed a specific range of laser treatment conditions in which tensile shear strength and fracture mode are stable.Although laser-treated adhesive joints showed cohesive failure similar to that observed in sandblasting or chem. treatment during the double cantilever beam test, the fracture toughness value was improved by a factor of 2 and 1.5, resp.The laser-induced microstructure on the aluminum interface contributed to the improvement of fracture toughness.Furthermore, observation of the adhesive layer using a microscopic mechanoluminescence measurement system revealed that changes in the 3D structure of the interface significantly altered the stress luminescence pattern reflecting strain.As a result, direct visualization of interface strengthening via laser processing was achieved.

1

项与 Technische Universität Braunschweig 相关的新闻（医药）

2022-06-15

·BioSpace

Ymmunobio Signs Collaboration Agreement with YUMAB

RIEHEN, SWITZERLAND, June 14, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM (carcinoembryonic antigen-related cell adhesion molecules) antibodies as anti-cancer treatments, today announced that it has signed a collaboration agreement with YUMAB GmbH, a privately-held German biotechnology company. YUMAB provides technologies and contract research for the development of fully human antibodies for all therapeutic fields. Within the scope of the collaboration, Ymmunobio AG will complement its antibody development by utilizing YUMAB’s expertise and platform for optimizing its antibodies. “We look forward to our collaboration being a productive complement to our capabilities,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “Ymmunobio shares a commitment with YUMAB to accelerate drug development through antibody optimization.” “We’re excited by the prospect of working with Ymmunobio to facilitate new pathways to antibody development,” said Dr. Thomas Schirrmann, YUMAB founder and CEO. “Ymmunobio shares our vision to accelerate drug discovery and ultimately improve patient outcomes.” Ymmunobio is developing a proprietary class of CEACAM1 immune agonistic antibodies in order to employ the immune system to fight cancer. Financial conditions of the agreement were not disclosed. ABOUT YMMUNOBIO Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany. ABOUT YUMAB YUMAB GmbH, a leading provider of contract research, technologies, and R&D services for the development of fully human, therapeutic antibodies, was founded in 2012 by scientists of the University of Braunschweig. A global player in human monoclonal antibody development, YUMAB is focused on the use of fully human antibodies for immunotherapies. For more information, please visit . Contact: Dr. Katrin Rupalla, info@ymmuno.bio

合作抗体

100 项与 Technische Universität Braunschweig 相关的药物交易

登录后查看更多信息

100 项与 Technische Universität Braunschweig 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年01月24日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

2

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

GluN1-GluN2B-Fc (Yumab) ( NMDA receptor )	抗-N-甲基-D-天冬氨酸受体脑炎更多	临床前
GluN1-GluN2A-Fc (YUMAB) ( NMDA receptor )	抗-N-甲基-D-天冬氨酸受体脑炎更多	临床前